<DOC>
	<DOCNO>NCT02379741</DOCNO>
	<brief_summary>The purpose study determine whether ADC-1013 ( agonistic human monoclonal IgG1 anti-CD40 antibody ) safe tolerable administer intratumorally ( repeated injection directly tumor tissue ) intravenously ( repeat dos directly vein ) patient advance solid tumor .</brief_summary>
	<brief_title>ADC-1013 First-in-Human Study</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Major Diagnosis advance solid tumor disease Performance status 01 ECOG scale Life expectancy least 3 month Major Organ transplant recipient Autoimmune disorder Other malignancy ( except localize prostate cancer , adequately treat basal skin cancer carcinoma insitu cervix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antineoplastic agent</keyword>
	<keyword>Physiological effect drug</keyword>
	<keyword>Therapeutic us</keyword>
	<keyword>Clinical Trial , Phase I</keyword>
	<keyword>Immunotherapy , Active</keyword>
	<keyword>CD40 Antigen</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Injections , Intralesional</keyword>
</DOC>